Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boston Scientific’s Alair system shows benefits in five-year study

Boston Scientific’s Alair system shows benefits in five-year study

5th September 2013

Boston Scientific has highlighted newly-published clinical trial data that underlines the safety and efficacy of its Alair bronchial thermoplasty (BT) system.

Results from the Asthma Intervention Research 2 (AIR2) study have been published in the Journal of Allergy and Clinical Immunology, showing that the benefits of this therapy option can last for at least five years.

Alair delivers thermal energy to the airway wall in a precisely controlled manner, decreasing the ability of the airway to constrict and thereby reducing the frequency and severity of asthma attacks.

Because of this, patients are less reliant on oral steroid treatment, which can have a number of undesirable side effects.

Mike Tringale, vice president of external affairs at the Asthma and Allergy Foundation of America, said: "The potential to provide a long-term reduction in emergency room visits, asthma attacks and their associated need for oral steroid treatment is very important to patients with asthma."

This comes after the firm completed patient enrolment for a new study assessing the 12-month safety and effectiveness of its Innova Self-Expanding Stent System last month.ADNFCR-8000103-ID-801634098-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.